Doraya is an innovative catheter device for treating patients resistant to diuretics with Acute Heart Failure (AHF) condition.

Project description

Improving the treatment of acute heart failure

Chronic heart failure is an important medical challenge that may lead to acute heart failure (AHF), the most common cause of hospitalisation for individuals over the age of 65. Standard treatment of AHF involves the administration of diuretics to facilitate fluid decongestion. However, a significant proportion of AHF patients have developed diuretic resistance. With the numbers of AHF cases projected to increase due to the ageing population, the EU-funded Doraya project has developed an innovative catheter device as an alternative to diuretic treatment, offering an optimal solution for restoring organ function.

Fields of science

• social sciences › sociology › demography › mortality
• medical and health sciences › clinical medicine › cardiology

Programme(s)

• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme
• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-1

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

REVAMP MEDICAL LTD

Net EU contribution

€ 50 000,00

Address

7 Giborey Israel St
4250407 Netania
Israel

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links

Other funding

€ 21 429,00